Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the Polio virus receptor (CD 155) and Nectin-2 (CD 112)

Blood

Volumn 105, Issue 5, 2005, Pages 2066-2073

  Pende, Daniela ^a   Spaggiari, Grazia Maria ^b   Marcenaro, Stefania ^b   Martini, Stefania ^b   Rivera, Paola ^b   Capobianco, Andrea ^b   Falco, Michela ^b   Lanino, Edoardo ^b   Pierri, Ivana ^b   Zambello, Renato ^b   Bacigalupo, Andrea ^b   Mingari, Maria Cristina ^b   Moretta, Alessandro ^b   Moretta, Lorenzo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD48 ANTIGEN; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NECTIN 2; POLIOVIRUS RECEPTOR; UNCLASSIFIED DRUG; VIRUS RECEPTOR; IL2RB PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR; LIGAND; MEMBRANE PROTEIN;

ARTICLE; CELL INTERACTION; CELL ISOLATION; CELL SIZE; CYTOLYSIS; DOWN REGULATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TARGET CELL; CELL COMMUNICATION; CELL CULTURE; CYTOTOXICITY; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CELL COMMUNICATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOID; LIGANDS; MEMBRANE PROTEINS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, INTERLEUKIN; RECEPTORS, VIRUS;

EID: 20144385362     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3548     Document Type: Article

References (38)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376.
2. Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol. 1997;9:24-34.
3. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol. 2002;3:6-8.
4. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004;23:255-259.
5. Ljunggren H-G. Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today. 1990;11:237-244.
6. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA-class I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619-648.
7. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359-393.
8. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1998;17:875-904.
9. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002;20:217-251.
10. Colonna M, Navarro F, Bellon T, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997;186:1809-1818.
11. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799.
12. Long EO. Signal sequences stop killer cells. Nature. 1998;391:740-743.
13. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA-class I phenotypes in human tumours. Immunol Today. 1997;18:89-95.
14. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-339.
15. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
16. Velardi A, Ruggeri L, Moretta A, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 2002;23:438-444.
17. Giebel S, Locatelli FW, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102-.814-819.
18. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
19. Moretta A, Biassoni R, Bottino C, Mingan MC, Moretta L Natural cytotoxicity receptors that trigger human NK-mediated cytolysis. Immunol Today. 2000;21:228-234.
20. Wu J, Song Y, Bakker ABH, et al. An activating immunoreceptor complex formed by NKG2D and DAP 10. Science. 1999;285:730-732.
21. Sivori S, Parolini S, Falco M, et al. 2B4 functions as a co-receptor in human natural killer cell activation. Eur J Immunol. 2000;30;787-793.
22. Vitale M, Falco M, Castriconi R, et al. Identification of NKp80, a novel triggering molecule expressed by human natural killer cells. Eur J Immunol. 2001;31:233-242.
23. Bottino C, Falco M, Parolini S, et al. NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative diseases. J Exp Med. 2001;194:235-246.
24. Marcenaro E, Augugliaro R, Falco M, et al. CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. Eur J Immunol. 2003;33:3367-3376.
25. Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4:573-581.
26. Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol Immunol. 2004;41:569-575.
27. Bauer S, Groh V. Wu J. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727-729.
28. Cosman D, Mulberg J, Sutherland C, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123-133.
29. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62:6178-6186.
30. Kubin M Z, Parshley D L, Din W, et al. Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48. Eur J Immunol. 1999;29:3466-3477.
31. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198:557-567.
32. Falco M. Marcenaro E, Romeo E. et al. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells. Eur J Immunol. 2004;34:1663-1672.
33. Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer celltriggering receptors in patients with acute myeloid leukemia. Blood. 2002;99:3661-3667.
34. Pende D, Parolini S, Pessino A, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190:1505-1516.
35. Leung W, Iyengar R, Turner V. et al. Determinant of anti-leukemia effects of allogeneic NK cells. J Immunol. 2004;172:644-650.
36. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102:1389-1396.
37. Vitale M, Carlomagno S, Falco M, et al. Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2. Int Immunol. 2004;16:1459-1466.
38. Igarashi T, Wynberg J, Srinivasan R, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004;104:170-177.